BKHAR

BKHAR is not a company's stock — it is the *rights* security (Nasdaq: BKHAR) of Black Hawk Acquisition Corp, a Cayman blank-check SPAC that 'neither engaged in any operations nor generated any revenues to date.' Each right converts to just one-fifth of an ordinary share, and only *if* an initial business combination closes. The MD&A confirms the only 'earnings' are trust interest income ($2.24M in FY2025), fully offset by G&A and sponsor fees to leave $1.33M net income (down 30.6% YoY) — an accounting artifact of parking IPO proceeds in T-bills, not a business. There is nothing to value here on fundamentals; the entire thesis is deal-completion odds.

The balance sheet screams distress for a vehicle that should be pristine. Cash is $0.00, current assets are just $50.8K against $1.48M current liabilities (up 1,988% YoY), stockholders' equity is -$3.85M, and total assets collapsed 66.9% to $23.9M as shares outstanding fell 53.5% to 4.15M. That combination is the fingerprint of massive public-shareholder redemptions: money is leaving the trust faster than the sponsor can close a deal, and management explicitly flags a $1.43M working-capital deficit and states it 'will need additional capital to satisfy its liquidity needs.' The heavy redemptions are the market's verdict on the announced merger with Vesicor Therapeutics (BCA signed April 26, 2025) — shareholders are voting with their feet rather than staying in for the biotech target.